Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Evogene Ltd. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
6.54
3.38
1.75
0.75
1.04
0.93
1.68
2.98
5.58
3.85
Cost of revenue
5.64
2.85
1.45
0.33
0.57
0.77
0.91
1.49
2.38
4.09
Gross profit
0.9
0.54
0.3
0.42
0.47
0.16
0.77
1.49
3.2
-0.24
Research and development
16.4
17
14.7
15.8
17.3
21.1
20.8
16.2
12.5
7.99
Selling, general and administrative
3.89
3.81
3.51
3.77
5.32
7.25
6.48
5.38
6.99
4.29
Operating income
-21.1
-21.9
-20
-21.2
-24.8
-31
-26.9
-22.2
-18.8
-14
Interest expense
0.89
1.01
2.21
0.56
2.95
1.41
3.33
0.93
3.36
1.93
Interest income
2.42
2.13
1.41
2.63
1.59
1.94
0.52
1.21
7.39
2.51
Pre-tax income
-19.6
-20.8
-20.8
-19.1
-26.2
-30.4
-29.8
-21.9
-14.8
-13.5
Income tax
0.04
0.01
0.03
0.02
0.03
0.01
0.09
0.02
0.01
0
Income from continuing operations
-22
-14.8
-13.5
Net income to minority interests
-0.05
-1
-2.83
-2.65
-3.21
-2.08
-1.57
0.66
Net income
-19.6
-20.8
-20.8
-18.1
-23.4
-27.8
-26.6
-23.9
-16.5
-8.49
EPS, basic
-7.63
-8.03
-8.03
-6.94
-8.22
-6.84
-6.44
-5.20
-2.90
1.08
EPS, diluted
-7.63
-8.03
-8.03
-6.94
-8.22
-6.84
-6.44
-5.20
-2.90
1.08
Balance sheet
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
3.24
3.44
5.81
34.7
46.2
32.3
29
20.8
15.3
13
Inventory
0
0.09
0.57
0.08
1.82
0.21
Total current assets
89.5
72.8
55.5
49
51.8
56.9
37.8
34.5
21.6
15.6
Property, plant and equipment
6.48
4.79
3.19
2.58
2.07
2.07
2.5
2.46
1.8
0.81
Lease right-of-use assets
2.67
1.87
2.11
1.57
0.98
2.45
1.82
Intangible assets
17.1
16.1
15.2
14.1
13.2
12.2
0
Total assets
96
77.6
58.7
71.4
71.9
76.3
56.1
51.1
39.9
20
Accounts payable
1.33
1.11
1.02
1
0.86
1.46
1.04
1.79
1.23
0.64
Total current liabilities
5.23
4.66
5.43
5.75
9.68
6.88
5.63
6.94
18.7
3.44
Lease liabilities
2.08
1.66
1.7
0.93
0.29
1.91
1.48
Total liabilities
8.7
8.22
8.39
11.1
15
12.9
21.3
22.4
25
8.07
Retained earnings
-96.2
-117
-138
-156
-179
-207
-234
-258
-274
-283
Shareholders' equity
87.3
69.4
50.1
50.1
46
53.7
27.9
12.1
-1.45
-0.08
Minority interests
0.25
10.1
10.8
9.77
6.86
16.6
16.3
12.1
Total equity
87.3
69.4
50.3
60.2
56.9
63.4
34.8
28.7
14.8
12
Total liabilities and equity
96
77.6
58.7
71.4
71.9
76.3
56.1
51.1
39.9
20
Cash flow statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-19.6
-20.8
-20.8
-19.1
-26.2
-30.4
-29.8
-26
-18.1
-7.83
Cash from operations
-11.7
-15.9
-15.2
-17.7
-19.5
-24.7
-23.7
-21.6
-19.7
-13.5
Capital expenditures
-0.81
-0.59
-0.37
-0.9
-0.68
-0.85
-1.17
-0.58
-0.63
-0.14
Cash from investing
4.03
15.2
17.4
37.1
9.42
-20.6
13.3
-4.54
9.62
17.7
Stock issued
10
0
0
Cash from financing
0.66
0.81
0.3
9.31
20.4
30.3
9.34
18.2
4.66
-6.6
Exchange rate effect
0.03
0.07
-0.11
0.16
1.21
1.1
-2.28
-0.25
-0.05
0.02
Net change in cash
-6.99
0.2
2.38
28.9
11.5
-13.9
-3.35
-8.21
-5.47
-2.35
Free cash flow
-12.5
-16.5
-15.5
-18.6
-20.2
-25.6
-24.8
-22.2
-20.3
-13.6
Interest paid
0.3
0.24
0.32
0.17
0.12
0.07
0.19
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $0.42 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
-6.3%
Gross profit / revenue.
Operating margin
-364.2%
Operating income / revenue.
Pre-tax margin
-350.3%
Pre-tax income / revenue.
Net margin
-220.2%
Net income / revenue.
FCF margin
-353.9%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-350.4%
Cash from operations / revenue.
Return on assets (ROA)
-28.3%
Net income / average total assets.
R&D / revenue
207.5%
Research and development expense / revenue.
SG&A / revenue
111.2%
Selling, general and administrative expense / revenue.
Capex / revenue
3.5%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-30.9%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
32.0%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
29.9%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-107.5%
Gross profit vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-49.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-29.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-22.5%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.54x
Current assets / current liabilities.
Quick ratio
3.76x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.76x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
$1.08
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$5.5M
Share price x shares outstanding.
Enterprise value
-$7.4M
Market cap + total debt - cash - short-term investments.
P/S
1.43x
Market cap / revenue.
FCF yield
-247.2%
Free cash flow / market cap.
Earnings yield
-153.8%
Net income / market cap (the inverse of P/E).
What was Evogene Ltd.'s revenue in fiscal 2025?
Evogene Ltd. reported revenue of $3.9M for fiscal 2025, 30.9% lower than the year before.
Was Evogene Ltd. profitable in fiscal 2025?
No. It reported a net loss of $8.5M.
How much free cash flow did Evogene Ltd. generate in fiscal 2025?
Cash from operations of $13.5M minus capital expenditures of $135.0K left free cash flow of -$13.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.